Blood-based Alzheimer's disease biomarkers and cognitive decline in essential tremor
Journal of Alzheimer’s Disease · 2026
DOI: 10.1177/13872877251404035 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, 2026. Verfasst von Tomer O Guy und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX, USA. Hauptthemen laut MEDLINE: Essential Tremor, Cognitive Dysfunction, Alzheimer Disease. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NINDS NIH HHS, Clinical Center.
Themen: Demenz
Abstract (Originalsprache)
Background
Two epidemiological studies demonstrated an association between essential tremor (ET) and prevalent dementia as well as substantially elevated risks of incident dementia among ET cases. At this early point, the underlying pathophysiology of ET-dementia is not known. In vivo biomarkers of Alzheimer's disease (AD) and neurodegeneration could help bridge the gap between the pathophysiological processes that present in the context of ET-dementia.
Objective
Examine blood concentrations of t-tau, p-tau181, p-tau217, Aβ 42/40 , neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) in ET with a range of cognitive diagnoses.
Methods
40 ET cases (mean age = 81.5 ± 7.3; including 20 normal cognition (NC), 12 cognitively normal with some weaknesses, 4 mild cognitive impairment, and 4 dementia) were enrolled in a study of cognitive performance in ET, during which phlebotomy was performed.
Results
Greater cognitive difficulty was associated with higher blood concentrations of p-tau217, p-tau181, GFAP, and NfL, and a lower Aβ 42/40 ratio ( p tests for trend < 0.05). Cases with dementia had marginally higher concentrations of p-tau217 ( p = 0.06) and higher concentrations of GFAP and NfL ( p < 0.05) than cases with NC. Furthermore, higher concentrations of p-tau217, GFAP, and NfL were associated with lower cognitive test scores across multiple cognitive domains ( p < 0.05).
Conclusions
Albeit based on a small sample of cases, our findings suggest a potential role of blood-based biomarkers as markers for cognitive function in ET patients. Cognitive decline in ET may be due to underlying neurodegenerative processes involving tau and perhaps Aβ pathology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
- Department of Neurology, Henry Ford Health System, Detroit, MI, USA.
- Peter O'Donnell Jr. Brain Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.
- Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY, USA.
- Gertrude H. Sergievsky Center, Columbia University Irving Medical Center, New York, NY, USA.
- Department of Neurology, Columbia University Irving Medical Center, New York, NY, USA.
Förderung
- NIA NIH HHS
- NINDS NIH HHS
- Clinical Center
Zitieren
APA
Guy, T. O., Ghanem, A., Berry, D. S., Hernandez, N. C., Sharma, V. D., Chapman, S., Cosentino, S., & Louis, E. D. (2026). Blood-based Alzheimer's disease biomarkers and cognitive decline in essential tremor. Journal of Alzheimer’s Disease. https://doi.org/10.1177/13872877251404035
Vancouver
Guy TO, Ghanem A, Berry DS, Hernandez NC, Sharma VD, Chapman S, et al. Blood-based Alzheimer's disease biomarkers and cognitive decline in essential tremor. Journal of Alzheimer’s Disease. 2026. doi:10.1177/13872877251404035
BibTeX
@article{Guy2026,
author = {Guy, Tomer O and Ghanem, Ali and Berry, Diane S and Hernandez, Nora C and Sharma, Vibhash D and Chapman, Silvia and Cosentino, Stephanie and Louis, Elan D},
title = {Blood-based Alzheimer's disease biomarkers and cognitive decline in essential tremor},
journal = {Journal of Alzheimer’s Disease},
year = {2026},
doi = {10.1177/13872877251404035}
}
EUVIMED